Search results for " tractament"

showing 10 items of 65 documents

Carta filosofica medico-chymica en que se demuestra que de los tiempos y experiencias se han aprendido los Mejores Remedios contra las Enfermedades .…

1687

Sign.: ^-^^^^2, 2[calderó]-5[calderó]2, A-Z2, Aa-Zz2, Aaa-Nnn2 Colofó dins d'orla Postil·les i reclams

Malalties Tractament Obres anteriors a 1800
researchProduct

Historia de las flegmasias ó inflamaciones crónicas : fundada en nuevas observaciones de clínica y de anatomía patológica

A port.: obra que presenta un cuadro razonado de las diversas variedades y combinaciones de estas enfermedades con sus diferentes métodos curativos Retrat de l’autor al vol. 1, signat: “ P. S. ; F. Suria" Sign.: [ ]4, a-c4, (1-39)4 ; (1-39)4 ; (1-40)4, (41)6 ; (1-34)4, (35)6 Pag.: vol. 1: XXVIII, 311 p., [1] f. de làm.; vol. 2: 312 p.; vol. 3: 332 p.; vol. 4: 276 p Antep. - Notes a peu de pàg. separades del text per filets

Malalties cròniques Diagnòstic S.XVIII-XIXAnatomia patològica Obres anteriors al 1900Malalties cròniques Tractament S.XVIII-XIXInflamació Obres anteriors al 1900
researchProduct

Relacion succinta tocante a los accidentes de la peste de Marsella su pronostico y curacion : remitida al cavallero de Langeron ... / por Mesieurs Ch…

1721

Sign.: a-d4, e2 Port. amb orla tip.

Malalties transmissibles Cura i tractament S.XVIII Obres anteriors a 1800Pesta bubònica Marsella (França) Obres anteriors a 1800
researchProduct

Discurso phissico medico politico que prueva no ser la fiebre Hectica enfermedad contagiosa : dize el modo y quando se deva purificar la ropa, que si…

1717

Sign.: A8 Port. orlada

Malalties transmissibles Tractament Obres anteriors a 1800
researchProduct

Discurso phissico medico politico que prueva no ser la fiebre Hectica enfermedad contagiosa : dize el modo y quando se deva purificar la ropa, que si…

Sign.: A8 Port. orlada

Malalties transmissibles Tractament Obres anteriors al 1800
researchProduct

Breve defensorio medico de vna receta sacada à luz por los Iusticia, y Iurados de la Villa de Vinaroz de su Medico ordinario el Dotor Iuan Ioseph Lo…

1684

Sign.: A6 Port. i text amb orla tip.

Malalts Tractament S.XVIII Obres anteriors a 1800Medicina Fòrmules i receptes S.XVIII Obres anteriors a 1800
researchProduct

Juicio critico del accidente que padece Don Pedro Zermeño litigado entre los doctores D. Joseph Guiral y Conejos y Don Thomas Exarhc ... / dedicalo …

1735

Sign.: [calderó]5, 2[calderó]4, A-C4, D3 Port. amb orla tip. El text de l'obra també orlat, però no els prelim.

Malalts Tractament S.XVIII Obres anteriors a 1800Medicina Pràctica professional S.XVIII Obres anteriors a 1800
researchProduct

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment…

2018

Vacunación; Narcolepsia; Simulación y modelado: en Vacunació; Narcolèpsia; Simulació i modelització Vaccination; Narcolepsy; Simulation and modeling Background & objectives Vaccine safety signals require investigation, which may be done rapidly at the population level using ecological studies, before embarking on hypothesis-testing studies. Incidence rates were used to assess a signal of narcolepsy following AS03-adjuvanted monovalent pandemic H1N1 (pH1N1) influenza vaccination among children and adolescents in Sweden and Finland in 2010. We explored the utility of ecological data to assess incidence of narcolepsy following exposure to pandemic H1N1 virus or vaccination in 10 sites that use…

Male:Other subheadings::Other subheadings::/epidemiology [Other subheadings]medicine.medical_treatmentlcsh:Medicine:Other subheadings::Other subheadings::/drug therapy [Other subheadings]medicine.disease_causeGeographical locations:enfermedades del sistema nervioso::trastornos del sueño-vigilia::disomnias::trastornos intrínsecos del sueño::trastornos de somnolencia excesiva::narcolepsia [NarcolepsiaENFERMEDADES]Influenza A Virus H1N1 Subtype0302 clinical medicineRisk FactorsPandemicMedicine and Health SciencesInfluenza A virusMedicinePublic and Occupational Health030212 general & internal medicineYoung adultChildlcsh:Science:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]Aged 80 and overVaccinesMultidisciplinaryIncidenceSimulation and ModelingIncidence (epidemiology)Vaccination:Otros calificadores::Otros calificadores::/epidemiología [Otros calificadores]Middle AgedVaccination and ImmunizationEuropeVaccinationInfectious DiseasesNeurologyInfluenza VaccinesChild PreschoolsymbolsEngineering and TechnologyFemaleSafetyNarcolèpsia - TractamentAdjuvantResearch ArticleAdultCanadaAsiaAdolescentInfectious Disease ControlImmunologyTaiwanResearch and Analysis MethodsYoung Adult03 medical and health sciencessymbols.namesakeAdjuvants ImmunologicEnvironmental healthInfluenza HumanHumansComputer SimulationEuropean UnionPoisson regressionAgedTrastorns del sonNarcolepsySwedenModels Statisticalbusiness.industrylcsh:RInfant NewbornNarcolèpsia - EpidemiologiaInfantBiology and Life SciencesDyssomniasAge GroupsR - MedicineRelative riskSignal ProcessingPopulation Groupingslcsh:QPreventive MedicinePeople and placesSleep Disordersbusiness030217 neurology & neurosurgeryPLOS ONE
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct